| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_79751aeaa9923745648e5ae7d9c35782 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-84
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D333-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D333-20 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D333-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D333-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-84 |
| filingDate |
1974-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1976-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29644dd89f91f7da01bb3a92e839ba01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12fdca7e11570b54cd4af3d81c547f11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_691319b0dac1008c55e9b6440d54ad48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e682778a37bc7722577a570b575fede |
| publicationDate |
1976-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-3941804-A |
| titleOfInvention |
1-Heteroarylsulphonyl-2-imino-imidazolidines |
| abstract |
Compounds of the class of 1-heteroarylsulphonyl-2-imino-imidazolidines which are substituted in the 3-position by an aliphatic or cycloaliphatic hydrocarbon radical, especially a cycloalkyl radical, and their pharmaceutically acceptable acid addition salts have valuable pharmacological properties. In particular, they possess hypoglycaemic activity and can be used for the treatment of hyperglycaemia in mammals. A specific embodiment is 1-[5-(2-butyramido-ethyl)-2-thienylsulphonyl]-2-imino-5-cyclohexyl-imidazolidine. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4409227-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4152440-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4059592-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4213986-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4325959-A |
| priorityDate |
1973-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |